Tempus AI Valuation

Q: What is the Fair Price of TEM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

TEM ($56.6) is trading above our estimate of [[fair value]] ($38.33)

Is TEM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TEM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: TEM ($56.6) is trading above our estimate of fair value ($38.33)

Significantly Below Fair Value: TEM is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TEM?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for TEM. This is calculated by dividing TEM's market cap by their current preferred multiple.
What is TEM's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	US$8.31b

TEM key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	13.9x
Enterprise Value/EBITDA	-12.8x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does TEM's PS Ratio compare to its peers?

The above table shows the PS ratio for TEM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	6.2x
MEDP Medpace Holdings	5.1x	12.5%	US$10.3b
RGEN Repligen	13.8x	13.5%	US$8.2b
BRKR Bruker	3.4x	8.9%	US$10.7b
CRL Charles River Laboratories International	2.5x	4.6%	US$10.2b
TEM Tempus AI	14.7x	25.0%	US$8.3b

Price-To-Sales vs Peers: TEM is expensive based on its Price-To-Sales Ratio (14.7x) compared to the peer average (6.2x).

Price to Earnings Ratio vs Industry

How does TEM's PE Ratio compare vs other companies in the US Life Sciences Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	18.1%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	18.1%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: TEM is expensive based on its Price-To-Sales Ratio (14.7x) compared to the US Life Sciences industry average (3.7x).

Price to Sales Ratio vs Fair Ratio

What is TEM's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TEM PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	14.7x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate TEM's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TEM forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	US$56.60	US$46.00 -18.7%	6.0%	US$50.00	US$40.00	n/a	8
Sep ’25	US$59.38	US$46.00 -22.5%	6.0%	US$50.00	US$40.00	n/a	8
Aug ’25	US$39.28	US$45.29 +15.3%	6.6%	US$50.00	US$41.00	n/a	7

Analyst Forecast: Target price is lower than the current share price.